An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorderThomas L Schwartz
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
Ann Clin Psychiatry 19:25-30. 2007
....
- Gamma hydroxy butyric acid and sodium oxybate used to treat posttraumatic stress disorder
Thomas L Schwartz
Department of Psychiatry, State University of New York, Upstate Medical University, Syracuse, New York, USA
CNS Spectr 12:884-6. 2007
- Psychiatric medication-induced obesity: treatment options
T L Schwartz
SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY 13210, USA
Obes Rev 5:233-8. 2004
..There is a clear need for larger studies on existing options, and future psychotropics without these side-effects are currently in the pipeline...
- Psychiatric medication-induced obesity: a review
T L Schwartz
SUNY Upstate Medical University, Department of Psychiatry, Syracuse, NY 13210, USA
Obes Rev 5:115-21. 2004
....
- Pharmacokinetics and drug interactions of the sedative hypnotics
Thomas L Schwartz
Upstate Medical University, State University of New York, Syracuse, New York, USA
Psychopharmacol Bull 37:5-9. 2003
..The results showed that orlistat, administered in 3 daily doses with meals, was safe, well-tolerated, and effective, resulting in an average weight loss of 35% during an acute treatment period of about 3 months...
- History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders
T L Schwartz
Psychiatry Department, SUNY Upstate Medical University, Syracuse, NY 13210, USA
Curr Pharm Des 11:255-63. 2005
..The following paper details the pharmacodynamic history of treating anxiety and also updates the reader as to the newer GABA-based approaches mentioned above...
- An open-label study of tiagabine as augmentation therapy for anxiety
Thomas L Schwartz
SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
Ann Clin Psychiatry 17:167-72. 2005
..Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the CNS, and agents that modulate GABA neurotransmission have shown promise in the treatment of anxiety disorders and are often used as augmentation agents...
- Tiagabine in anxiety disorders
Thomas L Schwartz
Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY, USA
Expert Opin Pharmacother 7:1977-87. 2006
..Tiagabine may be a useful addition to currently available drugs for anxiety; however, the data from small open-label investigations remain to be confirmed in larger controlled studies...
- Modafinil treatment for fatigue associated with fibromyalgia
Thomas L Schwartz
Department of Psychiatry, SUNY Upstate Medical Univeristy, Syracuse, New York 13210, USA
J Clin Rheumatol 13:52. 2007
- Safety and tolerability of extended-release venlafaxine in severe medical and surgical illness
Thomas Schwartz
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY 13210, USA
Psychosomatics 45:217-9. 2004
..This study attempted to determine if extended-release venlafaxine is safe for use in severely medically and surgically ill depressed patients...
- A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression
Mark S George
Department of Psychiatry, Medical University of South Carolina, 67 President Street 502 N, Charleston, SC 29425, USA
Biol Psychiatry 58:364-73. 2005
..To better understand these effects on long-term outcome, we compared 12-month VNS+TAU outcomes with those of a comparable TRD group...
- "A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia"
Thomas Schwartz
SUNY Upstate Medical University, Department of Psychiatry, 750 East Adams Street, Syracuse, NY 13210, USA
Int J Psychiatr Nurs Res 10:1146-50. 2004
..However, tolerability was much better with zaleplon as daytime residual side effects were less...
- Newly admitted psychiatric patient prescriptions and pharmaceutical sales visits
T L Schwartz
Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York 13210, USA
Ann Clin Psychiatry 13:159-62. 2001
..Furthermore, as sales visits increase in frequency, more of their medications may be started in newly admitted psychiatric outpatients...
- Psychiatric medication induced obesity: an aetiologic review
S Virk
Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
Obes Rev 5:167-70. 2004
..It is found that most psychotropic medications induce some weight gain, and clinicians are encouraged to utilize active interventions to alleviate the weight gain in order to prevent more serious obesity related comorbidities...
- Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study
A John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
Biol Psychiatry 58:355-63. 2005
..The need for effective, long-term treatment for recurrent or chronic, treatment-resistant depression is well established...
- An open-label study of adjunctive modafinil in patients with sedation related to serotonergic antidepressant therapy
Thomas L Schwartz
Department of Psychiatry, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
J Clin Psychiatry 65:1223-7. 2004
..This study assessed the use of modafinil as an adjunctive treatment in patients with MDD who reported sedation related to serotonergic antidepressant therapy...
- The role of atypical antipsychotics in the treatment of delirium
Thomas L Schwartz
Department of Psychiatry, S U N Y Upstate Medical University, Syracuse 13210, USA
Psychosomatics 43:171-4. 2002
..g., schizophrenia or bipolar disorder), but few studies have evaluated them in the treatment of delirium. This paper reviews the pertinent literature and summarizes tentative guidelines for novel antipsychotic use in delirium...
- Modafinil in the treatment of depression with severe comorbid medical illness
Thomas L Schwartz
Psychosomatics 43:336-7. 2002
- The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series
Thomas L Schwartz
Department of Psychiatry, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
Psychopharmacol Bull 36:53-7. 2002
..Like other anticonvulsant agents, tiagabine has been explored for use as a mood stabilizer and in panic disorder. This article presents a case series of five patients who were prescribed tiagabine for treatment-resistant anxiety...
- Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?
Prakash S Masand
Department of Psychiatry, Duke University Medical Center, Durham, NC 27710, USA
Psychosomatics 43:451-5. 2002
..Both groups had similar improvement in abdominal pain, constipation, diarrhea, incomplete emptying, and bloating/ abdominal distension. Paroxetine was very well tolerated...
- Use of atypical antipsychotics in a Veterans Affairs hospital
Thomas L Schwartz
Department of Psychiatry, SUNY Upstate Medical University, New York, USA
Prog Neuropsychopharmacol Biol Psychiatry 26:1207-10. 2002
....
- Effectiveness of orlistat versus diet and exercise for weight gain associated with antidepressant use: a pilot study
Thomas L Schwartz
J Clin Psychopharmacol 24:555-6. 2004
Psychiatric resident and attending diagnostic and prescribing practicesAdam C Tripp
SUNY Upstate Medical University, Syracuse, NY 13210, USA
Acad Psychiatry 32:214-7. 2008
..This study investigates whether two patient population groups, under resident or attending treatment, are equivalent or different in the distribution of patient characteristics, diagnoses, or pharmacotherapy...
- Prescribing conventional antipsychotics in the era of novel antipsychotics: informed consent issues
Prakash S Masand
Duke University Medical Center, Department of Psychiatry, Durham, North Carolina, USA
Am J Ther 9:484-7. 2002
..066, df = 2, Pearson chi(2) test). For patients who are receiving any antipsychotic therapy, discussions about the risks/benefits of treatments are integral for optimal treatment and medicolegal purposes...
- Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression
Usman Hameed
Department of Psychiatry, Upstate Medical University, 750 E Adams Street, Syracuse, NY 13210, USA
Ann Clin Psychiatry 17:77-81. 2005
..CONCLUSION: Antidepressants are very effective in treating depression in the primary care setting and may even be an effective and efficient treatment for adjustment disorder with depressed mood...
- Mifepristone, a glucocorticoid antagonist for the potential treatment of psychotic major depression
Nikhil D Nihalani
State University of New York, Upstate Medical University, Department of Psychiatry, Syracuse, New York, NY 13210 2375, USA
Curr Opin Investig Drugs 8:563-9. 2007
..In addition, in March 2005 a phase II study of mifepristone as a cognitive enhancer in AD was underway, and in May 2006 a proof-of-concept study in alleviating the weight gain associated with olanzapine had begun...
- Ziprasidone treatment of delirium
Laura Leso
SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
Psychosomatics 43:61-2. 2002
